International Journal of Chemotherapy Research and Practice

Aims and Scope

The International Journal of Chemotherapy Research and Practice aims to publish the latest research and advancements in chemotherapy and its related practices. The journal welcomes original research articles, reviews, case reports, and short communications that focus on all aspects of chemotherapy, including drug development, administration, pharmacokinetics and pharmacodynamics, drug interactions, side effects, and patient outcomes. The journal also welcomes studies related to the use of chemotherapy in various diseases, such as cancer, infections, and autoimmune disorders.

IJCP seeks to provide a forum for researchers to share the latest advances in chemotherapy research, discuss treatment strategies, and promote the translation of research into clinical practice. This journal aims to foster discussion and collaboration between scientific and clinical communities in the field of chemotherapy, and to provide a platform for researchers to disseminate information and innovations.

The scope of IJCP covers all aspects of chemotherapy, including fundamental and translational research, development of chemotherapeutic agents, biomarker identification, pharmacology and pharmacokinetics, clinical trials and outcomes, quality of life, and novel approaches to chemotherapy-related treatment. In addition, papers in related fields such as pharmacology and bioinformatics are welcomed.

Development and optimization of new chemotherapy drugs

Clinical trials and studies of chemotherapy in various types of cancer

Chemotherapy resistance mechanisms

Combination therapy with chemotherapy and other treatment modalities

Quality of life and side effect management in chemotherapy patients

Development of new delivery systems for chemotherapy

Economic and health policy implications of chemotherapy

IJCP publishes original research articles, reviews, case studies, and short communications.

IJCP is particularly interested in publishing research that has implications for clinical practice and/or which provides evidence-based approaches to treating cancer.

Few keywords are specified, which belong to the scope of the journal but not strictly restricted to them.

• Breast cancer
• Cancer
• Lung cancer
• Colorectal cancer
• Cervical carcinoma
• Antiviral therapy
• Chemoradiotherapy
• Chemoresistance
• Chemotherapy regimens
• Electrochemotherapy
• Chemotherapy resistance
• Antimicrobial chemotherapy
• Antifungal therapy
• Anticancer therapy
• Personalized chemotherapy
• Precision chemotherapy
• Antibacterial therapy
• Antiparasitic therapy
• Chemotherapy for cancer treatment
• Antibiotic resistance
• Cancer therapy
• Chemotherapy side effects
• Targeted therapies
• Gene therapy
• Personalized medicine
• Chemoprevention
• Drug discovery
• Antimicrobial agents
• Clinical trials
• Pharmacology
• Drug delivery systems
• Nanoparticles for drug delivery
• Anticancer agents
• Drug resistance mechanisms
• Multi-drug resistance
• Biomarkers for chemotherapy response
• Cancer stem cells
• Chemotherapeutic agents for rare diseases
• New chemotherapy drugs
• Combinatorial chemotherapy
• Drug toxicity
• Chemotherapy-induced peripheral neuropathy
• Chemotherapy for breast cancer
• Chemotherapy for lung cancer
• Chemotherapy for leukemia
• Chemotherapy for lymphoma
• Chemotherapy for sarcoma
• Chemotherapy for gastrointestinal tumors
• Chemotherapy for ovarian cancer
• Chemotherapy for pancreatic cancer
• Chemotherapy for brain tumors
• Chemotherapy for pediatric cancers
• Chemotherapy for melanoma
• Chemotherapy for prostate cancer
• Chemotherapy for bladder cancer
• Chemotherapy for head and neck cancers
• Chemotherapy for esophageal cancer
• Chemotherapy for thyroid cancer
• Chemotherapy for testicular cancer
• Chemotherapy for cervical cancer
• Chemotherapy for endometrial cancer
• Chemotherapy for liver cancer
• Chemotherapy for kidney cancer
• Chemotherapy for multiple myeloma